Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ABL1 T315I

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Acute Lymphocytic Leukemia	ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
ABL1 T315I	Acute Lymphocytic Leukemia	ABL1 T315I	Acute Lymphocytic Leukemia	imatinib Resistant: C2 – Inclusion Criteria imatinib Resistant : C2	imatinib Resistant: C2 – Inclusion Criteria imatinib Resistant : C2
ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	dasatinib Resistant: C3 – Early Trials dasatinib Resistant : C3	dasatinib Resistant: C3 – Early Trials dasatinib Resistant : C3
ABL1 T315I	Acute Lymphocytic Leukemia	ABL1 T315I	Acute Lymphocytic Leukemia	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4